All In Biotech

Drug Trial Radar · NCT07516418

Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age

A Phase 1, Randomized, Multi-center Study to Evaluate the Safety and Immunogenicity of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Healthy Participants 18 to 49 Years of Age

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

360

Actual

Start

Apr 15, 2026

Primary completion

Apr 4, 2027

Study completion Apr 4, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Apr 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and immunogenicity of different formulations of vaccines encoding the RSV monovalent antigen or the Flu hemagglutinin subtype 5 (H5) antigen in healthy participants aged 18 to 49 years. The total duration of study participation for each participant varies by stage and treatment arm. Stage 1: * For Arm 1, Arm 2, and Arm 3 the duration of study participation will be approximately 7 months for each participant. * For Arm 4, Arm 5, and Arm 6 the duration of study participation will be approximately 6 months for each participant. Stage 2: For all arms, the duration of study participation will be approximately 7 months for each participant.

Conditions

  • Respiratory Syncytial Virus (RSV)
  • Influenza A(H5N1)

Interventions

  • H5 Flu Investigational Medical Product (IMP) 1Biological

    Suspension for injection. Route of administration: Intramuscular (IM) injection

  • H5 Flu IMP 2Biological

    Suspension for injection. Route of administration: Intramuscular (IM) injection

  • H5 Flu IMP 3Biological

    Suspension for injection. Route of administration: Intramuscular (IM) injection

  • RSV IMP 4Biological

    Suspension for injection. Route of administration: Intramuscular (IM) injection

  • RSV IMP 5Biological

    Suspension for injection. Route of administration: Intramuscular (IM) injection

  • RSV IMP 6Biological

    Suspension for injection. Route of administration: Intramuscular (IM) injection

  • H5 Flu IMP 7Biological

    Suspension for injection. Route of administration: Intramuscular (IM) injection

  • H5 Flu IMP 8Biological

    Suspension for injection. Route of administration: Intramuscular (IM) injection

  • H5 Flu IMP 9Biological

    Suspension for injection. Route of administration: Intramuscular (IM) injection

  • H5 Flu IMP 10Biological

    Suspension for injection. Route of administration: Intramuscular (IM) injection

  • H5 Flu IMP 11Biological

    Suspension for injection. Route of administration: Intramuscular (IM) injection

  • H5 Flu IMP 12Biological

    Suspension for injection. Route of administration: Intramuscular (IM) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Presence of any unsolicited systemic Adverse Events (AEs) reported within 30 minutes after vaccinationTime frame: On Day 1
  2. Presence of solicited injection site reactions (ie, injection site pain, injection site erythema, injection site swelling, pre-listed in participant's diary and in the eCRF (electronic case report form)) occurring through 7 days after each vaccinationTime frame: Day 1 through day 8
  3. Presence of solicited systemic reactions (ie, fever, headache, and only new or worsened fatigue, myalgia, arthralgia, and chills pre-listed in the participant's diary and in the eCRF) occurring through 7 days after each vaccinationTime frame: Day 1 through day 8
  4. Presence of unsolicited AEs reported through 20 days after the first vaccination and after the second vaccination for IMPs with the Flu H5 antigenTime frame: Day 1 through day 21
  5. Presence of unsolicited AEs reported through 28 days after vaccination for IMPs with the RSV antigenTime frame: Day 1 through day 29
  6. Presence of SAEs (Serious Adverse Events) and AESIs (Adverse Events of Special Interest) throughout the study (ie, through 6 months after vaccination)Time frame: SAE: Screening day through day 202 (IMPs containing Flu H5 antigen), Screening day through day 181 (IMPs containing RSV antigen); AESI: Day 1 through day 202 (IMPs containing Flu H5 antigen), Day 1 through day 181 (IMPs containing RSV antigen)
  7. Presence of out-of-range biological test results (including shift from baseline values) through 7 days after each vaccinationTime frame: Screening through day 8
  8. Presence of AEs leading to study discontinuation throughout the study (ie, through 6 months after vaccination)Time frame: Screening through day 202 (IMPs containing Flu H5 antigen), Screening through day 181 (IMPs containing RSV antigen)
  9. RSV A and RSV B serum nAb (neutralizing antibodies) titers at pre-vaccination and 28 days post-vaccination in all participants receiving IMPs with the RSV antigenTime frame: Day 1 and day 29
  10. Flu H5 antibody (Ab) titer measured by hemagglutination inhibition (HAI) at pre-vaccination and 21 and 42 days post-vaccination in all participants receiving IMPs with the Flu H5 antigenTime frame: Day 1, day 22 and day 43
  11. Hemagglutination Inhibition (HAI) geometric mean titer ratio at 21 and 42 days post-vaccination relative to pre-vaccination for all participants receiving IMPs with the Flu H5 antigenTime frame: Day 1, day 22 and day 43
  12. Seroconversion rate based on Hemagglutination inhibition (HAI) antibody titers at pre-vaccination and 21 and 42 days post-vaccination in all participants receiving IMPs with the Flu H5 antigenTime frame: Day 1, day 22 and day 43
  13. Proportion of participants with Hemagglutination Inhibition (HAI) antibody titer ≥40 at pre-vaccination and 21 and 42 days post-vaccination in all participants receiving IMPs with the Flu H5 antigenTime frame: Day 1, day 22, and day 43
  14. Proportion of participants with detectable HAI antibody titer ≥10 at pre-vaccination and 21 and 42 days post-vaccination in all participants receiving IMPs with the Flu H5 antigenTime frame: Day 1, day 22, and day 43

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Site # 0361002

    Griffith, Queensland, Australia

  • Site # 0361001

    Herston, Queensland, Australia

  • Site # 0361003

    Morayfield, Queensland, Australia

  • Site # 0361005

    Sippy Downs, Queensland, Australia

  • Site # 03610004

    South Brisbane, Queensland, Australia

  • Site # 036006

    Taringa, Queensland, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.